Skip to main content
LLY
NYSE Life Sciences

Eli Lilly's Gene-Editing Cholesterol Therapy Shows Strong Early Results, Gets FDA Fast-Track

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1,064.59
Mkt Cap
$1.003T
52W Low
$623.78
52W High
$1,133.95
52W Position info
71% above low
Off High info
6.1% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

LLY sits 71% above its 52-week low of $623.78.

Summary

Eli Lilly announced positive Phase 1b clinical trial results for Verve-102, its experimental gene-editing therapy for high cholesterol. The treatment achieved up to an 88% reduction in PCSK9 protein levels and up to a 62% reduction in LDL cholesterol, with effects sustained for 18 months and no serious adverse events. The FDA has granted fast-track designation, accelerating its development. This adds a highly promising, innovative gene-editing asset to Eli Lilly's pipeline, building on recent successes with new drug approvals and strong financial performance. A Phase 2 study is expected to begin by year-end.

At the time of this announcement, LLY was trading at $1,064.59 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Nov 18, 2026, 3:04 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1,381.18
Real-time Price: $1,348.28 info
Change: -$32.90 (-2%) info
Market Cap: $1.267T info
LLY
Nov 17, 2026, 11:18 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1,416.23
Real-time Price: $1,348.28 info
Change: -$67.94 (-5%) info
Market Cap: $1.267T info
LLY
Nov 16, 2026, 6:52 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,455.36
Real-time Price: $1,348.28 info
Change: -$107.08 (-7%) info
Market Cap: $1.267T info
LLY
Nov 12, 2026, 8:30 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $1,452.70
Real-time Price: $1,348.28 info
Change: -$104.41 (-7%) info
Market Cap: $1.267T info
LLY
Nov 12, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1,447.85
Real-time Price: $1,348.28 info
Change: -$99.57 (-7%) info
Market Cap: $1.267T info